CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 60 enrolled
Drug / intervention
Metformin XR +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04850846
NCT04850846Phase 2Active
CompareCT.gov

A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Dana-Farber Cancer Institute·interventional·Posted Apr 20, 2021·Updated Feb 9, 2026

In Brief

A Phase 2 clinical trial evaluating Metformin XR and Placebo for Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. Active but no longer recruiting, targeting 60 participants across 7 sites.

Detailed Summary

The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) from developing multiple myeloma. The names of the study drug involved in this study is: * Metformin, extended release * Placebo ( a pill that has no active ingredients)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMonoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2Active
202220232024202520262027
First PostedApr 20, 2021
Enrollment StartApr 27, 2021
Primary CompletionJan 29, 2025
Study CompletionJul 31, 2027
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 5.2 years ago

Interventions

Metformin XRdrug

Orally by mouth

Placeboother

Orally by mouth